Palifermin vs EGF
Head-to-head comparison of Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) and EGF (Human Epidermal Growth Factor) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Palifermin | EGF |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) | Human Epidermal Growth Factor |
| Molecular Weight | 16.3 kDa | 6.0 kDa |
| Half-Life | 4–6 hours | minutes |
| Amino Acids | 140 | 53 |
| Typical Dose | 60 µg/kg/day | 0.04–0.1 mg/cm²/day |
| Route | Intravenous | Topical |
| Purity | ≥98% | ≥98% |
| Studies Count | 250 | 650 |
| Research Status | Clinical | Clinical |
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
EGF Benefits
- ✓re-epithelialization
- ✓fibroblast activation
- ✓angiogenesis support
- ✓faster ulcer closure
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
EGF Dosing
Topical daily|0.04–0.1 mg/cm²|short courses until granulation/closure
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
EGF Side Effects
- ⚠local irritation
- ⚠erythema
- ⚠theoretical hyperproliferation
- ⚠pain at site
Research Overview
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
EGF
Human and animal studies show EGF can accelerate epithelial migration and wound closure, especially in burns, ulcers, and mucosal injury. Its best evidence is for topical or local delivery because systemic exposure is brief and the effect is highly localized.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.